Illuminare Biotechnologies reported Phase 1 human data for Illuminare‑1, a fluorescent imaging agent that binds myelin to delineate peripheral nerves under blue light. The trial demonstrated rapid onset of nerve visualization and sustained contrast during surgery, according to an Innovation Spotlight featuring CMO Stewart McCallum. Illuminare‑1 aims to reduce iatrogenic nerve injury by improving intraoperative visualization; developers estimate millions of patients are at risk of nerve damage annually across procedures. The company plans broader clinical evaluation to assess utility across surgical specialties and to quantify impact on complication rates and functional outcomes.